Loading…
Legislative Progress
Introduced
September 24, 2026
Latest Action
September 24, 2026
Primary Sponsor
Nicholas A. LangworthyRepublican(NY)
Momentum (last 30 days)
2
score
0 actions · 1 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2026 · third_quarter · Health Issues
H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. H.R.10571, Surge to Save Newborns Act. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medical/Disease Research/Clinical Labs
H.R.10571, Surge to Save Newborns Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Advocacy on health care issues relating to genetics and genetic testing, including H.R. 4709, the Newborn Screening Saves Lives Reauthorization Act; H.R. 6208, Access to Genetic Counselor Services Act; H.R. 7118, Genomic Answers for Childrens Health Act; H.R. 2471, Right Dose Right Now Act; FY2027 Labor-HHS-Education Appropriations, and H.R. 10571, the Surge to Save Newborns Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES
2026 · third_quarter · Health Issues
FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act
Client expense: $240,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| CA |
| Josh Gottheimer | Democratic | NJ |
| Josh Riley | Democratic | NY |
| Kevin Mullin | Democratic | CA |
| Kim Schrier | Democratic | WA |
| Laura Gillen | Democratic | NY |
| Michael Lawler | Republican | NY |
| Mike Haridopolos | Republican | FL |
| Nanette Diaz Barragán | Democratic | CA |
| Raul Ruiz | Democratic | CA |
| Tom Barrett | Republican | MI |
| Troy Balderson | Republican | OH |
| Yvette D. Clarke | Democratic | NY |